Erythropoietin attenuates cardiac dysfunction by increasing myocardial angiogenesis and inhibiting interstitial fibrosis in diabetic rats

Cardiovascular Diabetology

Volumn 11, Issue , 2012, Pages

  Lu, Jing ^a   Yao, Yu yu ^a   Dai, Qi ming ^a   Ma, Gen shan ^a   Zhang, Shu feng ^a   Cao, Lei ^a   Ren, Li qun ^a   Liu, Nai feng ^a  

^a MEDICAL SCHOOL OF SOUTHEAST UNIVERSITY   (China)

Author keywords

Diabetes mellitus; Endothelial progenitor cell; Erythropoietin; Myocardial interstitial fibrosis; Transforming growth factor beta; Vascular endothelial growth factor

Indexed keywords

CD31 ANTIGEN; COLLAGEN TYPE 1; COLLAGEN TYPE 3; ERYTHROPOIETIN RECEPTOR; GLUCOSE; MESSENGER RNA; RECOMBINANT ERYTHROPOIETIN; TRANSFORMING GROWTH FACTOR BETA; VASCULOTROPIN;

ANGIOGENESIS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLOOD SAMPLING; COLLAGEN SYNTHESIS; CONTROLLED STUDY; DIABETES MELLITUS; DIASTOLIC DYSFUNCTION; ECHOCARDIOGRAPHY; ENDOTHELIAL PROGENITOR CELL; GLUCOSE BLOOD LEVEL; HEART MUSCLE CELL; HEART MUSCLE CONTRACTILITY; HEART MUSCLE FIBROSIS; HEART PROTECTION; HEART VENTRICLE HYPERTROPHY; IMMUNOHISTOCHEMISTRY; MALE; NONHUMAN; PROTEIN EXPRESSION; RAT; REAL TIME POLYMERASE CHAIN REACTION; WESTERN BLOTTING;

ANIMALS; ANTIGENS, CD31; BLOTTING, WESTERN; COLLAGEN TYPE I; COLLAGEN TYPE III; DIABETES MELLITUS, EXPERIMENTAL; ENDOTHELIAL CELLS; ERYTHROPOIETIN; FIBROSIS; GENE EXPRESSION REGULATION; HYPERTROPHY, LEFT VENTRICULAR; IMMUNOHISTOCHEMISTRY; INJECTIONS, SUBCUTANEOUS; MALE; MYOCARDIAL CONTRACTION; MYOCARDIUM; NEOVASCULARIZATION, PHYSIOLOGIC; RATS; RATS, SPRAGUE-DAWLEY; REAL-TIME POLYMERASE CHAIN REACTION; RECEPTORS, ERYTHROPOIETIN; RECOVERY OF FUNCTION; RNA, MESSENGER; STEM CELLS; TIME FACTORS; TRANSFORMING GROWTH FACTOR BETA; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VENTRICULAR DYSFUNCTION, LEFT; VENTRICULAR FUNCTION, LEFT; VENTRICULAR REMODELING;

EID: 84865819986     PISSN: None     EISSN: 14752840     Source Type: Journal    
DOI: 10.1186/1475-2840-11-105     Document Type: Article

References (32)

1. Cooper ME, Vranes D, Youssef S, Stacker SA, Cox AJ, Rizkalla B, Casley DJ, Bach LA, Kelly DJ, Gilbert RE. Increased renal expression of vascular endothelial growth factor (VEGF) and its receptor VEGFR-2 in experimental diabetes. Diabetes 1999, 48(11):2229-2239. 10.2337/diabetes.48.11.2229, 10535459.
2. Han B, Baliga R, Huang H, Giannone PJ, Bauer JA. Decreased cardiac expression of vascular endothelial growth factor and redox imbalance in murine diabetic cardiomyopathy. Am J Physiol Heart Circ Physiol 2009, 297(2):H829-H835. 10.1152/ajpheart.00222.2009, 19561313.
3. Yoon YS, Uchida S, Masuo O, Cejna M, Park JS, Gwon HC, Kirchmair R, Bahlman F, Walter D, Curry C, et al. Progressive attenuation of myocardial vascular endothelial growth factor expression is a seminal event in diabetic cardiomyopathy: restoration of microvascular homeostasis and recovery of cardiac function in diabetic cardiomyopathy after replenishment of local vascular endothelial growth factor. Circulation 2005, 111(16):2073-2085. 10.1161/01.CIR.0000162472.52990.36, 15851615.
4. Asghar O, Al-Sunni A, Khavandi K, Khavandi A, Withers S, Greenstein A, Heagerty AM, Malik RA. Diabetic cardiomyopathy. Clin Sci (Lond) 2009, 116(10):741-760.
5. Lipsic E, Schoemaker RG, van der Meer P, Voors AA, van Veldhuisen DJ, van Gilst WH. Protective effects of erythropoietin in cardiac ischemia: from bench to bedside. J Am Coll Cardiol 2006, 48(11):2161-2167. 10.1016/j.jacc.2006.08.031, 17161240.
6. Westenbrink BD, Oeseburg H, Kleijn L, van der Harst P, Belonje AM, Voors AA, Schoemaker RG, de Boer RA, van Veldhuisen DJ, van Gilst WH. Erythropoietin stimulates normal endothelial progenitor cell-mediated endothelial turnover, but attributes to neovascularization only in the presence of local ischemia. Cardiovasc Drugs Ther 2008, 22(4):265-274. 10.1007/s10557-008-6094-y, 18327705.
7. Wang W, Kagaya Y, Asaumi Y, Fukui S, Takeda M, Shimokawa H. Protective effects of recombinant human erythropoietin against pressure overload-induced left ventricular remodeling and premature death in mice. Tohoku J Exp Med 2011, 225(2):131-143. 10.1620/tjem.225.131, 21937860.
8. Kilkenny C, Browne WJ, Cuthill IC, Emerson M, Altman DG. Improving bioscience research reporting: the ARRIVE guidelines for reporting animal research. PLoS Biol 2010, 8(6):e1000412. 10.1371/journal.pbio.1000412, 2893951, 20613859.
9. Lang RM, Bierig M, Devereux RB, Flachskampf FA, Foster E, Pellikka PA, Picard MH, Roman MJ, Seward J, Shanewise JS, et al. Recommendations for chamber quantification: a report from the American Society of Echocardiography's Guidelines and Standards Committee and the Chamber Quantification Writing Group, developed in conjunction with the European Association of Echocardiography, a branch of the European Society of Cardiology. J Am Soc Echocardiogr 2005, 18(12):1440-1463. 10.1016/j.echo.2005.10.005, 16376782.
10. Yin M, Sillje HH, Meissner M, van Gilst WH, de Boer RA. Early and late effects of the DPP-4 inhibitor vildagliptin in a rat model of post-myocardial infarction heart failure. Cardiovasc Diabetol 2011, 10:85. 10.1186/1475-2840-10-85, 3198901, 21955567.
11. Hascall VC, Calabro A, Midura RJ, Yanagishita M. Isolation and characterization of proteoglycans. Methods Enzymol 1994, 230:390-417.
12. Tuo QH, Zeng H, Stinnett A, Yu H, Aschner JL, Liao DF, Chen JX. Critical role of angiopoietins/Tie-2 in hyperglycemic exacerbation of myocardial infarction and impaired angiogenesis. Am J Physiol Heart Circ Physiol 2008, 294(6):H2547-H2557. 10.1152/ajpheart.01250.2007, 18408125.
13. Mieno S, Boodhwani M, Robich MP, Clements RT, Sodha NR, Sellke FW. Effects of diabetes mellitus on VEGF-induced proliferation response in bone marrow derived endothelial progenitor cells. J Card Surg 2010, 25(5):618-625. 10.1111/j.1540-8191.2010.01086.x, 2958227, 20626511.
14. Zhu HF, Wan D, Luo Y, Zhou JL, Chen L, Xu XY. Catalpol increases brain angiogenesis and up-regulates VEGF and EPO in the rat after permanent middle cerebral artery occlusion. Int J Biol Sci 2010, 6(5):443-453. 2935667, 20827397.
15. Mohler ER, Lifeng Z, Medenilla E, Rogers W, French B, Bantly A, Moore JS, Yonghong H, Murashima M, Berns JS. Effect of darbepoetin alfa on endothelial progenitor cells and vascular reactivity in chronic kidney disease. Vasc Med 2011, 16(3):183-189. 10.1177/1358863X11408639, 21636677.
16. Fliser D, Haller H. Erythropoietin and treatment of non-anemic conditions-cardiovascular protection. Semin Hematol 2007, 44(3):212-217. 10.1053/j.seminhematol.2007.04.008, 17631185.
17. Burger D, Xenocostas A, Feng QP. Molecular basis of cardioprotection by erythropoietin. Curr Mol Pharmacol 2009, 2(1):56-69.
18. Westenbrink BD, Ruifrok WP, Voors AA, Tilton RG, van Veldhuisen DJ, Schoemaker RG, van Gilst WH, de Boer RA. Vascular endothelial growth factor is crucial for erythropoietin-induced improvement of cardiac function in heart failure. Cardiovasc Res 2010, 87(1):30-39. 10.1093/cvr/cvq041, 20139114.
19. Lindenblatt N, Menger MD, Klar E, Vollmar B. Darbepoetin-alpha does not promote microvascular thrombus formation in mice: role of eNOS-dependent protection through platelet and endothelial cell deactivation. Arterioscler Thromb Vasc Biol 2007, 27(5):1191-1198. 10.1161/ATVBAHA.107.141580, 17347485.
20. Westenbrink BD, Lipsic E, van der Meer P, van der Harst P, Oeseburg H, Du Marchie Sarvaas GJ, Koster J, Voors AA, van Veldhuisen DJ, van Gilst WH, et al. Erythropoietin improves cardiac function through endothelial progenitor cell and vascular endothelial growth factor mediated neovascularization. Eur Heart J 2007, 28(16):2018-2027. 10.1093/eurheartj/ehm177, 17576662.
21. Kim HA, Lim S, Moon HH, Kim SW, Hwang KC, Lee M, Kim SH, Choi D. Hypoxia-inducible vascular endothelial growth factor gene therapy using the oxygen-dependent degradation domain in myocardial ischemia. Pharm Res 2010, 27(10):2075-2084. 10.1007/s11095-010-0206-7, 20607367.
22. Imamura R, Moriyama T, Isaka Y, Namba Y, Ichimaru N, Takahara S, Okuyama A. Erythropoietin protects the kidneys against ischemia reperfusion injury by activating hypoxia inducible factor-1alpha. Transplantation 2007, 83(10):1371-1379. 10.1097/01.tp.0000264200.38926.70, 17519789.
23. Kobayashi H, Minatoguchi S, Yasuda S, Bao N, Kawamura I, Iwasa M, Yamaki T, Sumi S, Misao Y, Ushikoshi H, et al. Post-infarct treatment with an erythropoietin-gelatin hydrogel drug delivery system for cardiac repair. Cardiovasc Res 2008, 79(4):611-620. 10.1093/cvr/cvn154, 18541523.
24. Nakano M, Satoh K, Fukumoto Y, Ito Y, Kagaya Y, Ishii N, Sugamura K, Shimokawa H. Important role of erythropoietin receptor to promote VEGF expression and angiogenesis in peripheral ischemia in mice. Circ Res 2007, 100(5):662-669. 10.1161/01.RES.0000260179.43672.fe, 17293480.
25. Lin JS, Chen YS, Chiang HS, Ma MC. Hypoxic preconditioning protects rat hearts against ischaemia-reperfusion injury: role of erythropoietin on progenitor cell mobilization. J Physiol 2008, 586(Pt 23):5757-5769. 2655408, 18845609.
26. Kawachi K, Iso Y, Sato T, Wakabayashi K, Kobayashi Y, Takeyama Y, Suzuki H. Effects of erythropoietin on angiogenesis after myocardial infarction in porcine. Heart Vessels 2012, 27(1):79-88. 10.1007/s00380-011-0197-2, 22038108.
27. Zentilin L, Tafuro S, Zacchigna S, Arsic N, Pattarini L, Sinigaglia M, Giacca M. Bone marrow mononuclear cells are recruited to the sites of VEGF-induced neovascularization but are not incorporated into the newly formed vessels. Blood 2006, 107(9):3546-3554. 10.1182/blood-2005-08-3215, 16391016.
28. Wojakowski W, Landmesser U, Bachowski R, Jadczyk T, Tendera M. Mobilization of stem and progenitor cells in cardiovascular diseases. Leukemia 2012, 26(1):23-33. 10.1038/leu.2011.184, 21788948.
29. Li B, Zheng Z, Wei Y, Wang M, Peng J, Kang T, Huang X, Xiao J, Li Y, Li Z. Therapeutic effects of neuregulin-1 in diabetic cardiomyopathy rats. Cardiovasc Diabetol 2011, 10:69. 10.1186/1475-2840-10-69, 3170868, 21798071.
30. Strunz CM, Matsuda M, Salemi VM, Nogueira A, Mansur AP, Cestari IN, Marquezini MV. Changes in cardiac heparan sulfate proteoglycan expression and streptozotocin-induced diastolic dysfunction in rats. Cardiovasc Diabetol 2011, 10:35. 10.1186/1475-2840-10-35, 3100243, 21518435.
31. Asbun J, Villarreal FJ. The pathogenesis of myocardial fibrosis in the setting of diabetic cardiomyopathy. J Am Coll Cardiol 2006, 47(4):693-700. 10.1016/j.jacc.2005.09.050, 16487830.
32. Takeyama T, Takemura G, Kanamori H, Kawaguchi T, Ogino A, Watanabe T, Morishita K, Tsujimoto A, Goto K, Maruyama R, et al. Asialoerythropoietin, a nonerythropoietic derivative of erythropoietin, displays broad anti-heart failure activity. Circ Heart Fail 2012, 5(2):274-285. 10.1161/CIRCHEARTFAILURE.111.965061, 22343033.